DB00005 in the treatment of rheumatoid arthritis . INTRODUCTION : Biologic agents have transformed clinical outcomes in rheumatoid arthritis , and there are now several immune-modulating therapies available . Tumour necrosis factor-α ( P01375 -α ) inhibitors were the first biologic drug class licensed for the treatment of rheumatoid arthritis . DB00005 is a fusion protein composed of two P01375 receptors bound to the constant portion ( Fc ) of human immunoglobulin G ( IgG ) . AREAS COVERED : This article will consider the pharmacological properties of etanercept and the clinical efficacy data presented in clinical trials . Its safety in clinical practice will be reviewed . EXPERT OPINION : There is overwhelming evidence to support the use of etanercept in rheumatoid arthritis . Trial data demonstrate etanercept 's efficacy in reducing structural damage , improving clinical outcomes and inducing remission . Optimal response to therapy is seen when used in combination with methotrexate and when initiated early . DB00005 is an attractive therapeutic option given the excellent safety profile , reduced immunogenicity and ease of administration .